Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN)
Daniel L. Hertz(GTx (United States)), Maryam B. Lustberg(Yale Cancer Center), Nadeen T. Ali(University of Khartoum), Yu Ke(National University of Singapore), Kathryn J. Ruddy(Mayo Clinic in Arizona), Sara Faithfull(King's College London), Charles L. Loprinzi(Mayo Clinic in Arizona), Alexandre Chan(University of California, Irvine), Sheila Marie McGlown(Yahoo (United Kingdom)), Lisa Grech(Deakin University), Susanna B. Park(The University of Sydney), Daniel S. Childs(Mayo Clinic in Arizona)
Cited by 63
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2017|1.3k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2014|1.2k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
|Journal of Clinical Oncology|2020|1.1k
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
|European Heart Journal|2021|589